Clinical trial
Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting…
NCT04225312 · Amsterdam UMC, location VUmc, Other · Unknown status
Key facts
| NCT number | NCT04225312 |
|---|---|
| Title | Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis |
| Official title | Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis |
| Acronym | SUPERNEXT |
| Lead sponsor | Amsterdam UMC, location VUmc, Other |
| Collaborators | Stichting MS Research Innovatiefonds Zorgverzekeraars Stichting Treatmeds |
| Status | Unknown status |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Relapsing Remitting Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Personalized extended interval dosing of natalizumab, Standard interval dosing |
| Enrollment | 300 |
| Start date | Feb 3, 2020 |
| Primary completion | Mar 1, 2025 |
| Completion | Mar 1, 2025 |
| First posted | Jan 13, 2020 |
| Last update posted | Apr 27, 2023 |
| Countries | Netherlands |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: